G. Mikael Dolsten's most recent trade in Agilent Technologies Inc. was a trade of 634 Common Stock done at an average price of $151.4 . Disclosure was reported to the exchange on Sept. 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agilent Tech | Dr. G. Mikael Dolsten, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 151.38 per share. | 04 Sep 2026 | 634 | 4,923 (0%) | 0% | 151.4 | 95,972 | Common Stock |
| Agilent Tech | Dr. G. Mikael Dolsten, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 135.42 per share. | 29 May 2026 | 1,600 | 5,548 (0%) | 0% | 135.4 | 216,672 | Common Stock |
| Apellis Pharma Inc | G. Mikael Dolsten | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 24,135 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | G. Mikael Dolsten | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 14,312 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | G. Mikael Dolsten | Director | 14 May 2026 | 14,312 | 0 (0%) | 0% | - | Common Stock | ||
| Agilent Tech | Dr. G. Mikael Dolsten, M.D.,PhD | Director | Grant, award, or other acquisition of securities at price $ 111.75 per share. | 19 Mar 2026 | 2,158 | 7,138 (0%) | 0% | 111.8 | 241,157 | Common Stock |
| Agilent Tech | Dr. G. Mikael Dolsten, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 149.81 per share. | 01 Dec 2025 | 2,600 | 4,973 (0%) | 0% | 149.8 | 389,511 | Common Stock |
| Agilent Tech | Dr. G. Mikael Dolsten, M.D.,PhD | Director | Grant, award, or other acquisition of securities at price $ 121.18 per share. | 14 Mar 2025 | 1,819 | 7,549 (0%) | 0% | 121.2 | 220,426 | Common Stock |
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | 12 Sep 2024 | 137,760 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | 12 Sep 2024 | 137,760 | 137,760 | - | - | Stock Appreciation Rights | ||
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | 12 Sep 2024 | 126,794 | 126,794 | - | - | Stock Appreciation Rights | ||
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | 12 Sep 2024 | 126,794 | 0 | - | - | Stock Appreciation Rights | ||
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.04 per share. | 28 Feb 2024 | 21,437 | 321,729 (0%) | 0% | 27.0 | 579,656 | Common Stock |
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | 27 Feb 2024 | 214,880 | 214,880 | - | - | Stock Appreciation Rights | ||
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | 27 Feb 2024 | 189,867 | 189,867 | - | - | Stock Appreciation Rights | ||
| Pfizer | Dr. G. Mikael Dolsten, M.D. | President R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.76 per share. | 23 Feb 2024 | 24,822 | 343,166 (0%) | 0% | 27.8 | 689,059 | Common Stock |